Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor

Pathos obtains worldwide rights from Novo Nordisk for the development of CBP/p300 inhibitor, FT-7051 Chicago – Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform drug development, announced today that it has entered into a worldwide license agreement to develop FT-7051, a small molecule CBP/p300 inhibitor program from Novo Nordisk as Pathos’ first clinical-stage asset in its pipeline. FT-7051 was developed by Forma Therapeutics, which was acquired by Novo Nordisk in 2022, and